Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOKYO Pharma Limited

OKYO Pharma Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.42 USD 0.04 ( 2.90%)
Last update at 2026-11-11T21:00:00Z
VOLUME
59856
Market Cap
71.37M

Momentum Score

…

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.31
Low
1.45
High
52 Week Price Range
1.32
Low
3.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.38
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-6.69M
Debt / Equity
-1.08
ROE
-263.78%
Net Debt
-14.59M
ROCE
-68.65%
Diluted EPS TTM
-0.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -8.94M -7.97M -16.80M -13.28M -4.73M
Net income -8.95M -4.71M -16.83M -13.27M -4.13M
Selling general administrative - - - - 4.92M
Gross profit -6.69M -0.00M -7.51M - -
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit -8.47M -7.09M -15.75M -13.19M -4.73M
Ebitda -8.47M -7.08M -15.75M -13.18M -4.73M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M 0.00M
Operating income -8.50M -7.19M -15.75M -13.19M -4.73M
Other operating expenses 8.50M 7.19M 15.75M 13.19M 4.73M
Interest expense 0.47M 0.88M 1.05M 0.10M 0.00M
Tax provision 0.01M -3.26M 0.02M -0.01M -0.79M
Interest income 0.03M 0.01M 0.00M 0.00M 0.00M
Net interest income -0.44M -0.88M -1.05M -0.10M 0.00M
Income tax expense 0.01M -3.26M 0.02M -0.01M -0.60M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.81M 7.19M 8.24M 13.19M 4.73M
Cost of revenue 6.69M 0.00M 7.51M - -
Total other income expense net -0.44M -0.78M -1.05M -0.10M -
Net income from continuing ops -8.95M -4.71M -16.83M -13.27M -5.43M
Net income applicable to common shares - - - - -3.98M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 20.98M 3.68M 1.54M 5.20M 3.27M
Other current assets 0.21M 0.23M 0.13M - 0.54M
Total liab 8.64M 9.23M 7.42M 7.26M 1.03M
Total stockholder equity 12.34M -5.55M -5.88M -2.05M 2.24M
Other current liab 1.51M 1.33M 1.29M 2.65M 0.47M
Common stock 173.56M 146.72M 143.11M 131.39M 94.38M
Capital stock 173.56M 146.72M 143.11M 131.39M 123.98M
Retained earnings -151.97M -143.02M -142.52M -125.70M -85.59M
Cash 14.59M 1.56M 0.83M 4.05M 2.06M
Total current liabilities 8.64M 9.23M 7.42M 7.26M 1.03M
Net debt -14.59M -1.56M -0.83M -1.83M -2.06M
Short term debt - - - 2.22M -
Short long term debt - - - 2.22M -
Short long term debt total - - - 2.22M -
Other stockholder equity 2.88M 146.72M 143.11M 3.71M 1.83M
Property plant equipment - - - - 0.00M
Total current assets 20.97M 3.68M 1.54M 5.20M 3.27M
Net tangible assets - - - - 2.24M
Short term investments 6.00M 0.00M - - -
Net receivables 0.17M 1.89M 0.58M 0.98M 0.67M
Accounts payable 7.14M 7.90M 6.13M 2.39M 0.56M
Accumulated other comprehensive income -12.13M -9.24M -6.47M -11.45M -8.38M
Non currrent assets other - - 0.00M - -
Non current assets total 0.01M 0.00M 0.00M 0.01M 0.00M
Capital lease obligations - - - - 0.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments -6.00M -0.00M 0.00M -0.01M -0.00M
Change to liabilities - - - - -0.18M
Total cashflows from investing activities -6.01M -0.00M - - -0.00M
Net borrowings 0.00M 0.95M 0.00M - -
Total cash from financing activities 25.02M 2.66M 6.21M 9.32M 1.64M
Net income -8.94M -7.97M -16.83M -13.28M -4.73M
Change in cash 13.03M 0.73M -3.22M 1.34M -3.19M
Begin period cash flow 1.56M 0.83M 4.05M 2.70M 5.24M
End period cash flow 14.59M 1.56M 0.83M 4.05M 2.06M
Total cash from operating activities -5.94M -1.81M -9.49M -7.70M -4.16M
Issuance of capital stock 25.02M 1.71M 6.21M 7.32M 0.00M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities -6.00M - - - -
Change to account receivables - -0.09M 0.44M - 0.02M
Other cashflows from financing activities - 1.71M 0.01M 2.00M 1.64M
Change to netincome - - - - 0.74M
Capital expenditures 0.01M 0.00M 0.00M 0.01M 0.00M
Change in working capital -0.63M 1.63M 2.67M 3.95M -0.78M
Stock based compensation 1.61M 0.73M 1.12M 1.27M 1.31M
Other non cash items 2.03M 3.79M 3.54M 0.11M 0.04M
Free cash flow -5.94M -1.81M -9.49M -7.70M -4.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
OKYO
OKYO Pharma Limited		 0.04
2.90%		 1.42 - - - 5.70 -4.29
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

35a Albemarle St, London, United Kingdom, W1S 4JE

44 20 7495 2379

https://okyopharma.com

5

Name Title Year Born
Dr. Gary S. Jacob Ph.D. CEO & Exec. Director 1947
Mr. Michael Paul Beck Founder 1957
Ms. Keeren Shah Chief Financial Officer 1977
Dr. Rajkumar Patil Ph.D. Chief Scientific Officer 1958
Dr. Gary S. Jacob Ph.D. CEO & Executive Director 1947
Ms. Keeren Shah Chief Financial Officer 1976
Dr. William A. Clementi Ph.D., Pharm.D. Chief Operating Officer NA
Dr. Rajkumar Patil Ph.D. Chief Scientific Officer 1959
Mr. Robert J. Dempsey M.B.A. CEO & Executive Director NA
Dr. Gary S. Jacob Ph.D. Chief Development Officer & Director 1947

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…